New research data surrounding the medication Retatrutide , specifically the high-dose formulation ZPHC ZPHC, indicate a significant benefit on body mass reduction and linked chronic factors. Researchers anticipate that this dual agonist , affecting both GLP-1 and GIP pathways , could offer a not